文献速递肿瘤 PET/CT甲状腺核医学

乳腺癌患者中[18F]FES与[18F]FDG PET/CT的头对头比较:新时代已经到来?

Head-to-Head comparison of [18F]FES and [18F]FDG PET/CT in breast cancer patients: has a new era come?
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-03-11

该综述以头对头方式系统比较了[18F]FDG与[18F]FES PET/CT在乳腺癌患者中的诊断与预后价值,检索PubMed、Scopus和Web of Science截至2025年1月,共纳入20篇论文、806例接受两种PET的乳腺癌患者。初步分期中[18F]FES PET/CT似乎比[18F]FDG更准确,[18F]FES表达为预后良好的积极因素,尤其在[18F]FDG摄取低时,[18F]FES在浸润性小叶癌中似有前景。

要点

  • 共20篇论文、806例乳腺癌患者接受了[18F]FDG与[18F]FES两种PET检查。
  • 初步分期中[18F]FES PET/CT似乎比[18F]FDG更准确。
  • [18F]FES表达为预后良好的积极因素,尤其当[18F]FDG摄取低时。

核心结论

  • 这些发现强调[18F]FES作为[18F]FDG互补影像生物标志物的潜力,作者主张进一步研究以标准化PET指标并完善两者联合的临床效用。

研究设计与样本

  • 本综述为系统综述,检索PubMed、Scopus和Web of Science数据库截至2025年1月,无时间限制、对纳入研究的患者数量无限制,以识别比较[18F]FDG与[18F]FES PET在乳腺癌患者中诊断价值的相关文章。
  • 纳入的影像学研究采用针对系统综述修改版的批判性评估技能计划(CASP)清单进行分析。

主要发现

  • 共评估20篇论文;基于CASP分析,研究质量参差不齐。
  • 共806例乳腺癌患者接受了[18F]FDG与[18F]FES两种PET检查,涉及分期/诊断价值和预后价值等不同疾病场景。
  • 在疾病的初步分期中,[18F]FES PET/CT似乎比[18F]FDG更准确。
  • 在预后领域,[18F]FES表达是预后良好的积极因素,尤其当[18F]FDG摄取量低时。
  • [18F]FES在浸润性小叶癌患者中作为分子显像剂似乎有前景。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 基于CASP分析,研究质量参差不齐。
  • 作者主张进一步研究以标准化PET指标并完善两者联合的临床效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This review systematically compared, in a head-to-head manner, the diagnostic and prognostic performance of [18F]FDG and [18F]FES PET/CT in breast cancer (BC) patients. METHODS: A systematic literature search was conducted in PubMed, Scopus, and Web of Science databases up to January 2025, without temporal limitations or restrictions on the number of patients in the included studies, to identify relevant articles comparing the diagnostic value of [18F]FDG and [18F]FES PET in BC patients. Selected imaging studies were analyzed using a modified version of the Critical Appraisal Skills Programme checklist dedicated to systematic reviews. RESULTS: A total of 20 papers were evaluated. Based on the CASP analysis, the quality of the study was variable. Totally, 806 patients affected by BC underwent both [18F]FDG and [18F]FES PET. Different setting of disease were considered, such as staging/diagnostic and prognostic value. In the initial staging of disease, [18F]FES PET/CT seemed to be more accurate than [18F]FDG. In the prognostic field, [18F]FES expression was a positive factor for the better prognosis, in particular when the amount of [18F]FDG uptake was low. [18F]FES seemed to be promising as a molecular agent in patients affected by invasive lobular BC. CONCLUSION: These findings underscore the potential of [18F]FES as a complementary imaging biomarker to [18F]FDG, advocating for further studies to standardize PET metrics and refine their combined clinical utility.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Guglielmo P, Mazzola R, Darwish SS, et al. Head-to-Head comparison of [18F]FES and [18F]FDG PET/CT in breast cancer patients: has a new era come? Eur J Nucl Med Mol Imaging. 2025. PMID: 40067459. doi:10.1007/s00259-025-07186-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。